For Dow Jones or the WSJ, the best place to look is under the company briefing books section, where DJ and WSJ, as well as Press releases, are linked in a company specific manner. The DJ report of the Targretin NDA submission is at:
interactive.wsj.com
(although the above URL doesn't show up as underlined and blue, if you copy and paste it into your browser's location box, it will take you to the article as long as you have an online subscription to WSJ interactive)
The "good news" part of the report is:
Phase II/III trials of Targretin showed that 48% of the 152 patients in the study improved 50% on the treatment.
Ligand Pharmaceuticals said its Targretin product is "central" to its revenue growth in the U.S. and Europe for the next few years.
If approved, Ligand will market the capsules in the U.S., Canada and some European countries.
Ferrer Internacional S.A. would market the product in Spain, Portugal, Greece and Central and
South America.
The company will submit a Marketing Authorization Application for Targretin to the European Agency for the Evaluation of Medicinal Products in the second half of 1999.
The company is also testing the drug on breast cancer and psoriasis, and plans to file a New Drug Application for Targretin gel in the fourth quarter."
The rest of the report is background, which is also favorable written. |
